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ABSTRACT
Introduction: Most of the health-related quality of life
(HRQoL) measures for patients with inflammatory
bowel disease (IBD) were designed to be used in
outpatient settings and are therefore not suitable for
use in acute inpatient settings. None of the currently
used clinical severity indices for patients with IBD have
been properly validated. The aim of this study was to
describe the development of a new HRQoL
questionnaire and a clinical severity index for patients
with ulcerative colitis or Crohn’s disease that were
short, valid and suitable at any stage of their disease.
The new HRQoL and disease severity index will be
easily used at the point of care, and invaluable
monitoring tools for clinical care, audit and research.
Methods and analysis: This is a prospective
multisite validation study of two new outcome
measures, the Crohn’s and Colitis quality of life (CCQ)
questionnaire and the Clinical IBD severity score
(CISS). We plan to recruit patients with ulcerative
colitis or Crohn’s disease. The questionnaire items will
be selected through extensive literature review and a
focus group involving patients, methodologists,
statisticians and IBD specialists. The CCQ questionnaire
will be completed by patients attending IBD clinics,
having endoscopy procedures or when admitted to
hospital. CISS will be completed by clinicians while
assessing patients with IBD. Psychometric analysis will
be carried out to test the validity and reliability of the
questionnaires and to determine the potential to
produce shorter versions of CISS and CCQ. The
construct validity of CCQ will be tested against short
form-12 and the European Quality of Life Five
Dimensions. The construct validity of CISS will be
tested against biochemical markers, clinical and
endoscopic indices to assess severity.
Ethics: This study was approved by the South East
Wales Research Ethics Committee (Ref 11/WA/0239).
INTRODUCTION
Inﬂammatory bowel disease (IBD) affects
approximately one person in every 250 in
the UK population.1 The cost of IBD to the
National Health Service (NHS) has been
estimated at about £720 million per annum,
based on the prevalence and an average cost
of £3000/year/patient.2 The lifetime medical
costs associated with the care of IBD are
comparable with major chronic diseases such
as diabetes mellitus or cancer.2 Antitumour
necrosis factor α drugs are new and effective
biological treatments for both ulcerative
colitis (UC)3 and Crohn’s disease (CD),4 but
the long-term outcomes are still unknown
ARTICLE SUMMARY
Article focus
▪ None of the currently used clinical severity
indices for patients with inflammatory bowel
disease (IBD) have been properly validated.
▪ Most of the health-related quality of life (HRQoL)
measures for patients with IBD have been
designed for use in outpatient settings and are
therefore not suitable for use in acute inpatient
settings.
▪ This article describes the protocol for a prospect-
ive multisite validation study of two new
outcome measures, the Crohn’s and colitis
HRQoL (CCQ) questionnaire and the Clinical IBD
severity score (CISS).
Key messages
▪ The main focus of the article is the development
and validation of two outcome measures to
assess the quality of life and disease severity of
patients with IBD.
▪ This article provides an insight into the methods
used to develop and validate new outcome mea-
sures which can be applied to any disease.
Strengths and limitations of this study
▪ CISS will be the first fully validated clinical sever-
ity index for patients with IBD.
▪ The CCQ will be the first HRQoL tool that will be
applicable to all types and presentations of IBD.
▪ It may be difficult to recruit adequate numbers of
patients with less common presentations of IBD
like perianal Crohn’s disease or patients with
extra-intestinal manifestations.
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and there are a number of safety issues.5 Therefore, the
National Institute for Health and Clinical Excellence has
recommended the establishment of a Registry for
patients with IBD treated with biological therapy.6
Assessment of response to treatment will require the
measurement of both health-related quality of life
(HRQoL) and disease severity.
HRQoL questionnaires are often employed as mea-
sures of health status and are important outcome mea-
sures in clinical trials. They should form an integral part
of any outcome monitoring efforts but are often omitted
from large-scale registries because of constraints on the
amount of data these registries can collect. To facilitate
the adoption of HRQoL measures in large IBD regis-
tries, it is important to develop instruments which are
short and easy to complete, yet valid, reliable and applic-
able to all IBD patients.
IBD has a great impact on the quality of life as it is
not curable and follows an unpredictable, relapsing and
remitting course with signiﬁcant variation in the pattern
and complexity of symptoms that may affect each
patient, sometimes leading to hospital admission,
surgery and bowel resection, which may leave the
patient with a stoma. There are several speciﬁc HRQoL
measurement tools for patients with IBD.7–9 However, all
of them have been designed for use in the outpatient
setting with stable patients and there is no HRQoL
instrument that is validated for use both in the commu-
nity and by patients who are acutely ill or have a stoma
or perianal disease.
In clinical practice, assessing disease severity is an
important part of IBD management and a standardised
and quantitative evaluation of the severity of IBD is
needed for the registry. Owing to the varied presenta-
tions of IBD, a number of clinical indices have been put
forward using different parameters which are based on
different principles.10 11 Currently available disease
severity indices measure disease severity at a single point
of time rather than over a longer time period, which is
an important outcome to assess quality of care.
Therefore, a new index that assesses the chronic severity
of IBD over a long period of time is needed. A recently
reported disability measurement tool for patients with
IBD has good correlation with other quality of life and
disease severity tools, but has not been validated on
acutely unwell patients, only those seen in outpatients.12
An instrument has been developed to assess the cumula-
tive bowel damage in Crohn’s disease, but this index is
speciﬁc for Crohn’s disease and requires imaging
reports for completion.13 In order to be widely utilised
and generalisable, the index should include as few items
as possible which are easily obtainable in any clinical
setting and applicable to the majority of patients. An
index should also possess the required psychometric
properties such as validity and reliability.14 15 In IBD,
there are several different disease severity indices avail-
able.10 11 However, none of them have been properly
validated. Therefore, for a successful IBD registry, there
is a need for a short yet reliable and valid severity score
index to assess response to treatment and to detect early
relapse for all types and presentations of IBD.
AIM
The aim of the study was to develop valid and reliable
HRQoL and disease severity measurement tools that are
suitable for use with patients at any stage of their IBD.
These tools will be easily recorded at the point of care
to support their use for a registry of patients with IBD.
OBJECTIVES OF THE STUDY
To validate an HRQoL questionnaire (Crohn’s and
Colitis Quality of Life (CCQ) questionnaire) and derive
a short form (Short CCQ) that is suitable for acute and
stable patients with IBD and covers patients with a stoma
or ﬁstula.
To validate a single clinical severity index (Clinical
IBD severity index (CISS)) and derive a short form that
is suitable for all types and presentations of IBD.
METHODS AND ANALYSIS
Developing the outcome measures
Crohn’s and colitis HRQoL questionnaire
The initial version of the Crohn’s and Colitis
health-related quality of life questionnaire will be based
on the UK Inﬂammatory Bowel Disease Questionnaire9
that was developed and validated in 2000. An extensive
literature review will be carried out to identify supple-
mentary items to reﬂect the wide range and frequency
of symptoms of IBD when patients are seen as outpati-
ents or inpatients with perianal disease and with a
stoma. The ﬁrst draft of CCQ will be as inclusive as
Box 1 Commonly used clinical severity indices in the
literature
1. Ulcerative colitis
▪ Truelove and Witts severity index26
▪ Powell tuck index27
▪ Simple clinical colitis severity index21
▪ Lichtiger score28
▪ Clinical activity index (CAI)24
▪ Physician global assessment29
▪ Improvement based on individual symptom score30
▪ Ulcerative colitis clinical severity score31
▪ Seo score32
▪ Mayo clinic activity score23
2. Crohn’s disease
▪ Crohn’s disease activity index33
▪ Harvey Bradshaw index20
▪ Van Hees index34
▪ The Cape Town index35
▪ Fistula Drainage assessment36
▪ Perianal Disease Activity Index (PDAI)37
▪ Perianal Crohn’s disease Activity Index (PCDAI)22
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possible to cover all patients with IBD. We will validate
CCQ with a wider group of patients to include patients
with both CD and UC as well as patients with a stoma
and Crohn’s perianal disease. The questionnaire will be
examined by IBD specialists, methodologists and statisti-
cians to ensure good face and content validity of the
items. To ensure that the resulting questionnaire is clear
to patients, we will conduct a feasibility study, asking a
small sample of patients to complete the questionnaires.
Quality of life will thus be presented as a simple score
that will be derived from items completed by patients
with different IBD phenotypes in a broad spectrum of
settings. The score will enable monitoring over time and
comparative assessment across different UK locations.
Clinical IBD severity score
The development of Clinical IBD Severity Score (CISS)
will follow a clinimetric approach.14 15 Items will be
selected through a review of 17 existing clinical severity
indices commonly used in studies for UC and CD (box 1).
To ensure that the selected items are applicable to patients
with IBD, a focus group of at least six IBD specialists from
different UK hospitals, statisticians and methodologists will
review these items and ensure good face and content valid-
ity. CISS will assess the acute and chronic severity of IBD. It
will have supplementary questions for perianal disease (to
be used when applicable). CISS will be the ﬁrst clinical
severity index to include all presentations of patients with
IBD in one single index.
Recruitment
This is a prospective multicentre study which will be
carried out over a 3-year period. Sites will be invited and
patients will be recruited over a 24-month period. Data
analysis and production of the ﬁnal version of the ques-
tionnaires will be carried out in the following
12 months. We will recruit patients with UC or CD.
Invitations will be sent to teaching and general district
hospitals across the UK. We will aim to recruit at least
four different UK sites. Patients’ medical records will be
reviewed to conﬁrm their eligibility as below:
Inclusion criteria
▪ Conﬁrmed diagnosis of UC, CD or indeterminate
colitis.
▪ Age 18 years and above.
▪ Not in a vulnerable group (such as people with
mental illness or memory problems, learning difﬁcul-
ties or physical disabilities).
▪ Able to consent.
Exclusion criteria
▪ Patients without a deﬁnite diagnosis of UC, CD or
indeterminate colitis.
▪ Age less than 18 years.
▪ Patients within a vulnerable group (such as people
with mental illness or memory problems, learning dif-
ﬁculties or physical disabilities).
▪ Unable to consent.
If patients meet the inclusion criteria, they will be
invited to participate in the study when they attend out-
patients or are admitted to hospital. Patients will be
asked to give written consent following an oral and
written explanation of the study.
The long version of the CCQ questionnaire will be
completed by patients while they are in hospital, in out-
patients or at home. Patients will also complete the
generic short form 12 (SF12)16 and European Quality of
Life Five Dimensions (EQ5D)17 questionnaires. They
will be asked to complete the same questionnaires
within 6 weeks after the initial completion to check test–
retest reliability and responsiveness.
CISS will be recorded by the healthcare professionals
when reviewing patients in clinic or on the ward. CISS
will be recorded again in 2–6 weeks after the initial com-
pletion in order to check CISS test–retest reliability and
responsiveness.
Sample size
When validating a questionnaire, it is important that the
sample used is representative of the population in which
the instrument is to be used. There are no general cri-
teria for the required sample size in a validation study,15
which is typically based on the assumption that the
number of respondents should exceed the number of
items in the questionnaire by at least a factor of three.18
Some authors suggest that rather than the overall
sample size, it is the ratio of participants to items that is
important and recommend a 10 to 1 ratio for each
item.19 We anticipate that CISS will have 17 different
items and CCQ will have 32 different items. We will
therefore aim to recruit a minimum of 170 patients and
320 patients for the validation study of initial versions of
CISS and CCQ, respectively.
Psychometric analysis
Data will be analysed using the Statistical Package for
Social Sciences (SPSS) V.19 licensed to Swansea
University. The main components of psychometric ana-
lysis will be:
Internal consistency
Internal consistency is a measure of reliability. It mea-
sures the degree of correlation between different items
in the scale. Internal consistency will be assessed by
item–total correlations and Cronbach α. Items with
item–total correlation below 0.2 or more than 0.8 will be
rejected14 15 as they add little information to the scale.
Items will also be considered for rejection if more than
80% or less than 20% of patients gave the same response
because they would not be able to differentiate different
levels of severity. Items that are ambiguous or found dif-
ﬁcult to answer will be considered for removal or
rewording. Cronbach α of the resulting scale should be
>0.7.15 Item discrimination power, which is the ability of
items to discriminate between patients with different
level of severity, should be >0.415; otherwise, it will be
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considered for rejection. We will carry out stepwise
regression of the total scores on the individual items
and select the items that represent 95% of the variation
in the scores to produce short versions of the CCQ and
CISS.15
Validity
Construct validity refers to the correlation of the scale with
other instruments that are believed to assess the same attri-
bute with high degrees of validity and reliability.13 It is com-
monly measured using the Pearson correlation coefﬁcient
(r). Construct validity will be accepted if Pearson correlation
is 0.4–0.8.14 15 Lower correlations mean either one of the
tests has low validity or the two tests are measuring different
phenomena, while high correlations mean the two tests are
very similar and the new scale is not needed. Construct val-
idity of CCQ will be assessed using SF1216 and EQ5D.17
Construct validity of CISS will be checked using biochemical
markers: C reactive protein, white cell count, haemoglobin,
albumin and clinical indices: Harvey Bradshaw index20 (for
CD), Simple clinical colitis activity index21 (for UC) and
perianal disease activity index22 (for perianal CD). These
clinical indices will be selected because they are easy to use
and widely cited10 11 in the literature. When patients
undergo endoscopy, the following endoscopic indices will
be recorded: Mayo clinic score,23 Rachmilewitz scores24 in
UC and simple endoscopic score25 in CD.
Test–retest reliability or reproducibility
Reproducibility is used to assess reliability of the test
applied on two occasions. To measure reproducibility,
CCQ and CISS will be administered to 20% of patients
on two occasions. There should be no overall change in
their clinical condition between these two intervals. For
CCQ, patients will be asked if their health has changed
since they last ﬁlled the questionnaires. For CISS, we will
use physician’s global assessment to assess if patients’
conditions have changed or not. Patients with no
change will be included in the reproducibility analysis
using the intraclass correlation coefﬁcient. For practical
reasons, we will allow a period of 2–6 weeks after the
ﬁrst assessment or since the ﬁrst questionnaire was com-
pleted. Previous studies have illustrated that a period of
less than 2 weeks is not reliable as patients might
remember their answers and select them again.14 15
Therefore, we expect to include patients with a quies-
cent to moderate IBD for the reproducibility analysis
because patients with severe IBD will be more likely to
have their disease changed or have surgery within
2 weeks. A value of intraclass correlation of 0.7514 15 will
be accepted.
Responsiveness
Responsiveness is the ability to detect change. This will
be computed by applying CCQ and CISS to 20% of
patients on two occasions. For CCQ, patients will be
asked if their health has changed since they last ﬁlled
the questionnaires. For CISS, we will use physician’s
global assessment to assess if patients’ conditions have
changed or not. Patients whose clinical conditions have
changed will be included in the responsiveness analysis
using the responsiveness ratio. Responsiveness ratio will
be calculated by dividing the mean change in scores for
patients who reported a change with the SD of the
scores of those who remained stable.15 A ratio more
than 0.5 will be accepted.14 15 For practical reasons, we
will allow a maximum of 6 weeks after the ﬁrst assess-
ment or since the ﬁrst questionnaire was completed.
Interobserver reliability
This is a measure of reliability to assess the degree of
consistency between different observers. We will check
the interobserver reliability of CISS on 20% of patients
using interclass correlation. Two observers will use CISS
to assess the same group of patients. We will divide the
patients into two groups. The first group will be assessed
by a physician and a specialist nurse, while the second
group will be assessed by two physicians. A correlation of
>0.75 will be acceptable.15
Ethics and dissemination
This study has been approved by the South East Wales
Research Ethics Committee (Reference 11/WA/0239).
NHS code of conﬁdentiality and Data protection will be
adhered to. Once patients are identiﬁed, all personal
details will be anonymised. Only study-related staff will
have access to the data. Access will be permitted to
appropriately qualiﬁed personnel and in accordance
with the Data Protection Act 1998. All data acquisition,
storage and transmission will comply with the Data
Protection Act.
We are committed to publishing our results as widely
as possible in peer-reviewed journals and to ensuring
that appropriate recognition is given to everyone who
works on the study.
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